scholarly journals Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

2011 ◽  
Vol 17 (8) ◽  
pp. 2270-2280 ◽  
Author(s):  
Marieke F. Fransen ◽  
Marjolein Sluijter ◽  
Hans Morreau ◽  
Ramon Arens ◽  
Cornelis J.M. Melief
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Slow Release ◽  
Local Delivery ◽  
Local Activation ◽  
Agonistic Cd40 Antibody ◽  
Tumor Eradication

scholarly journals Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication

2017 ◽  
Vol 5 (2) ◽  
pp. 127-136 ◽  
Author(s):  
Ainhoa Arina ◽  
Theodore Karrison ◽  
Eva Galka ◽  
Karin Schreiber ◽  
Ralph R. Weichselbaum ◽  
...  
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Cd4 T Cells ◽  
Tumor Eradication

scholarly journals T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.

1996 ◽  
Vol 183 (5) ◽  
pp. 2361-2366 ◽  
Author(s):  
J C Becker ◽  
J D Pancook ◽  
S D Gillies ◽  
K Furukawa ◽  
R A Reisfeld
Keyword(s):  
T Cells ◽  
T Cell ◽  
Cd8 T Cells ◽  
Nk Cell ◽  
Interleukin 2 ◽  
Tumor Model ◽  
Melanoma Metastases ◽  
Tumor Eradication

Induction of a T-cell mediated antitumor response is the ultimate goal for tumor immunotherapy. We demonstrate here that antibody-targeted IL2 therapy is effective against established pulmonary and hepatic melanoma metastases in a syngeneic murine tumor model. The effector mechanisms involved in this tumor eradication are not dependent on NK cells, since the therapeutic effect of antibody-IL2 fusion protein was not altered in NK cell-deficient mice. In contrast, T cells are essential for the observed antitumor effect, since therapy with antibody IL2 fusion proteins is unable to induce tumor eradication in T cell-deficient SCID mice. In vivo depletion studies characterized the essential effector cell population further as CD8 + T cells. Such CD8 + T cells, isolated from tumor bearing mice after antibody-directed IL2 therapy, exerted a MHC class I-restricted cytotoxicity against the same tumor in vitro. These data demonstrate the ability of antibody-targeted IL2 delivery to induce a T cell-dependent host immune response that is capable of eradicating established melanoma metastases in clinically relevant organs.

scholarly journals Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

2016 ◽  
Vol 76 (20) ◽  
pp. 6017-6029 ◽  
Author(s):  
Elham Beyranvand Nejad ◽  
Tetje C. van der Sluis ◽  
Suzanne van Duikeren ◽  
Hideo Yagita ◽  
George M. Janssen ◽  
...  
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Tumor Eradication

scholarly journals Tumor Eradication by Hepatitis B Virus X Antigen-Specific CD8+T Cells in Xenografted Nude Mice

2003 ◽  
Vol 170 (3) ◽  
pp. 1183-1190 ◽  
Author(s):  
Eunyoung Chun ◽  
Jihyun Lee ◽  
Hong Seok Cheong ◽  
Ki-Young Lee
Keyword(s):  
T Cells ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Nude Mice ◽  
Cd8 T Cells ◽  
B Virus ◽  
Tumor Eradication

scholarly journals Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma

2020 ◽  
Vol 218 (1) ◽  
Author(s):  
Catalina Lee-Chang ◽  
Jason Miska ◽  
David Hou ◽  
Aida Rashidi ◽  
Peng Zhang ◽  
...  
Keyword(s):  
T Cells ◽  
B Cells ◽  
Cd8 T Cells ◽  
Glioma Cells ◽  
Cross Presentation ◽  
Tumor Bearing ◽  
Efficient Alternative ◽  
Secondary Lymphoid Organs ◽  
Tumor Eradication ◽  
Strong Ability

Immunotherapy has revolutionized the treatment of many tumors. However, most glioblastoma (GBM) patients have not, so far, benefited from such successes. With the goal of exploring ways to boost anti-GBM immunity, we developed a B cell–based vaccine (BVax) that consists of 4-1BBL+ B cells activated with CD40 agonism and IFNγ stimulation. BVax migrates to key secondary lymphoid organs and is proficient at antigen cross-presentation, which promotes both the survival and the functionality of CD8+ T cells. A combination of radiation, BVax, and PD-L1 blockade conferred tumor eradication in 80% of treated tumor-bearing animals. This treatment elicited immunological memory that prevented the growth of new tumors upon subsequent reinjection in cured mice. GBM patient–derived BVax was successful in activating autologous CD8+ T cells; these T cells showed a strong ability to kill autologous glioma cells. Our study provides an efficient alternative to current immunotherapeutic approaches that can be readily translated to the clinic.

Author response for "4‐1BB costimulation promotes bystander activation of human CD8 T cells"

2020 ◽  
Author(s):  
Manuel Reithofer ◽  
Sandra Rosskopf ◽  
Judith Leitner ◽  
Claire Battin ◽  
Barbara Bohle ◽  
...  
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Author Response ◽  
Bystander Activation
Sign in / Sign up

Export Citation Format

Share Document